Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Net Margin (2020 - 2025)

Lyell Immunopharma's Net Margin history spans 5 years, with the latest figure at 226580.0% for Q3 2025.

  • For Q3 2025, Net Margin fell 9558000.0% year-over-year to 226580.0%; the TTM value through Sep 2025 reached 798982.93%, down 49599245.0%, while the annual FY2024 figure was 548667.21%, 37670183.0% down from the prior year.
  • Net Margin for Q3 2025 was 226580.0% at Lyell Immunopharma, up from 548300.0% in the prior quarter.
  • Across five years, Net Margin topped out at 23.42% in Q4 2022 and bottomed at 2139533.33% in Q3 2022.
  • The 5-year median for Net Margin is 209724.0% (2023), against an average of 448089.51%.
  • The largest annual shift saw Net Margin tumbled -213775871bps in 2022 before it surged 192980933bps in 2023.
  • A 5-year view of Net Margin shows it stood at 1673.1% in 2021, then surged by 99bps to 23.42% in 2022, then crashed by -1721920bps to 403261.54% in 2023, then crashed by -342bps to 1783881.82% in 2024, then soared by 87bps to 226580.0% in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Net Margin are 226580.0% (Q3 2025), 548300.0% (Q2 2025), and 764357.14% (Q1 2025).